Fig. 10.1 Treatment of malignant sex cord-stromal tumors. *Fertility-preserving surgery—affected-side salpingo-oophorectomy + omentectomy + peritoneal cytology + detailed intra-abdominal examination. **Lymph node dissection (biopsy) can be omitted. Reprint with permission from ref. 21 10.3 Malignant Ovarian…
Fig. 16.1 Cycle of frailty [66], reprinted with permission of Oxford University Press Fig. 16.2 Hypothesized molecular and physiological association with frailty [67], reprinted with permission of John Wiley and…
Fig. 14.1 Treatment strategy of recurrent epithelial ovarian cancer Table 14.1 Important clinical trials for recurrent ovarian cancer Study (y) Drug n Primary endpoint RR(%) PFS(M) OS(M) Comments Platinum-sensitive disease…
Fig. 12.1 The history of primary chemotherapy for epithelial ovarian cancer In contrast to paclitaxel, fractionated weekly dosing of carboplatin remains a challenging regimen. The Multicentre Italian Trials in Ovarian…
Author Year Number of patients Positive rate(%) Stage (%) Positive rate(%) la lb lc PEN PAN Sakuragi, et al 2000 78 5.1 3.2 – 6.4 0 5.1 Suzuki, et al…
High-grade serous Low-grade serous High-grade endometrioid Low-grade endometrioid Clear cell Mucinous Unspecified carcinoma No. 1501 70 64 14 58 16 166 BRCA1 (%) 10.3 4.3 6.3 0 6.9 0…
Fig. 8.1 Flowchart of fundamental strategies for the management of epithelial ovarian cancer. Cited from Komiyama et al. [3] with slight modifications 8.2 Surgical Management 8.2.1 Early (Localized to the Ovary)-Staged…
Fig. 7.1 HR-deficient and HR-proficient tumors of high-grade serous ovarian carcinoma [8] HR pathway proficient tumors with CCNE1 amplification were common in primary resistant and refractory cases [7]. Inactivation of…
St Bartholomew’s Hospital trial The Boston study Ref. [9] [10] Published 1996 2003 Design Single arm prospective study Single arm prospective study. Subjects The low-risk asymptomatic women > or = 45 years…
Amount of fibroglandular tissue (FGT) Almost entirely fat Scattered fibroglandular tissue Heterogeneous fibroglandular tissue Extreme fibroglandular tissue Background Parenchymal Enhancement Level Minimal Mild Moderate Marked Symmetric or Asymmetric Focus Masses…
